cas号： 53164-05-9 ，名称：阿西美辛的性质/作用/用途-化学加百科

阿西美辛

阿西美辛基本信息
CAS号	53164-05-9	分子式	C21H18ClNO6
分子量	415.82400	精确质量	415.08200
PSA	94.83000	LogP	3.47050

我要卖该产品我要采购该产品

充值推广查看更多供应商

基本信息制备方法与用途物化性质安全信息合成路线毒性 MSDS 结构与计算数据上下游

基本信息展开↓

CAS号：: 53164-05-9
3D弹球模型：: 立即前往扯扯看
分子式：: C21H18ClNO6
分子量：: 415.82400
中文名称：: 阿西美辛
英文名称：: acemetacin
中文别名：: 阿西美辛;
[1-(对氯苯甲酰基)-5-甲;
[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-基]乙酰氧基乙酸;
1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酸羧甲酯;
1-(对氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-乙酸羧甲酯;
1-(4-氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-乙酸羧甲基酯;
炎痛美新
英文别名：: acemetacin;
TVX-1322;
aximeixin;
BAY f4975;
Acemetacin;
acemix;
glycolic acid ester of indomethacin;
Emflex;
tv1322;
Solart;
rantudil;
[1-(4-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetoxyacetic Acid;
k-708;
1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid carboxymethyl ester;
rheumibis;
1-(4-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic Acid Carboxymethyl Ester
精确分子量/精确质量：: 415.08200
极性分子表面积/PSA：: 94.83000
油水分配系数/LogP：: LogP值指的是某物质在正辛醇/水两相体系中的分配系数的对数值，反映了物质在油水两相中的分配情况。其中、LogP值越大，说明该物质越亲油；反之，LogP值越小，则说明该物质越亲水。
贝尔斯坦号/MDL：: MFCD00151473
EINECS：: 258-403-4
PubChem：: 24890474
InChI：: InChI=1/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)

生产制备方法及用途展开↓

制备方法

方法1:以在吲哚美辛的合成中得到的N-(4-甲氧基苯基)-4-氯苯甲酰肼为原料,和(3-乙酰基丙酰氧基)乙酸苄酯(其制备见方法3)环合,得到[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酰氧基]乙酸苄酯(I)。得到的苄酯(I)溶于冰醋酸中,在室温下在钯-炭催化剂上进行加氢,当氢吸收停止后,过滤去催化剂,滤液减压浓缩,残液加入石油醚中重结晶,得阿西美辛精品,熔点149.5～150.5℃,收率93%。方法2:以吲哚美新为原料。在搅拌下,将180g(0.503mo1)吲哚美新溶于900ml无水二甲基甲酰胺,加入35g(0.253mo1)磨细和干燥的碳酸钾,在50℃下搅拌45min。在15min中,滴入128g(0.56mo1)溴乙酸苄酯,在50℃下搅拌3h。过滤,滤液浓缩,剩余物溶于氯仿,用水洗至中性,无水硫酸钠干燥。浓缩,异丙醚-乙酸乙酯重结晶,得228g化合物(I),收率89.5%,熔点96℃。 60g(0.12mo1)化合物(I)溶于700ml乙酸乙酯,加入6g 5%钯-炭催化剂,在40℃下氢化1h,吸收约2.921L氢气(20℃)。过滤,浓缩,往剩余物加入石油醚(40～60℃),使结晶完全,并在冰箱中放置12h。过滤,先空气中干燥,后真空干燥,得46g阿西美辛,收率93%,熔点150～153℃。方法3:以对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯为原料。(3-乙酰基丙酰氧基)乙酸苄酯的制备。93.5g(0.68mo1)干燥碳酸钾悬浮于650ml无水二甲基甲酰胺,加热至40℃,在70min内滴入116.1g(1.0mo1)3-乙酰基丙酸。加毕,冷至30℃,加入229.1g(1.0mo1)2-溴乙酸苄酯。在50℃下反应4h。过滤除去无机盐,用甲苯提取。提取液浓缩,剩余物溶于400ml二氯甲烷,水洗至中性,无水硫酸钠干燥。浓缩,剩余物溶于。1000ml异丙醚,加入冷至-25℃的1500ml石油醚(40～60℃),于-15℃下放置1h。过滤,在22℃下真空干燥,得235g(3-乙酰基丙酰氧基)乙酸苄酯,收率89%,熔点31.5～32.5℃,沸点176～178℃/1.20kPa。 26.3g(0.19mo1)对甲氧基苯肼溶于125ml冰乙酸和450ml水,在搅拌下,滴入50g(0.19mo1)(3-乙酰基丙酰氧基)乙酸苄酯,再搅拌1h。用甲苯提取,提取液水洗至中性,干燥,浓缩,得75.5g棕色油状的化合物(Ⅱ),直接用于下列反应。将化合物(Ⅱ)直接溶于125ml无水吡啶,加入500ml无水乙醚,再在0℃加入43.5g对氯苯甲酰氯在250ml无水乙醚的溶液,在氮气保护下回流2h,冷却,水洗至中性,干燥,浓缩,得95g化合物(Ⅲ)的粗品。无需提纯,直接用于下步反应。将化合物(Ⅲ)直接溶于380ml乙酸,在80℃下加热5min。减压浓缩,剩余物溶于氯仿,用碳酸氢钠溶液洗,并水洗至中性。用氧化铝层析,氯仿洗脱。浓缩后用乙醚重结晶,得10.6g化合物(I)。从对甲氧基苯肼计,收率11%。化合物(I)再如方法2还原为阿西美辛。方法4:对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯也可先环合,再对氯苯甲酰化。 45.7g(0.26mo1)对甲氧基苯肼盐酸盐和69.2g(0.26mo1)(3-乙酰基丙酰氧基)乙酸苄酯溶于260ml乙酸,先在28℃搅拌42h,再在50℃搅拌5h。蒸出150～180ml溶剂后,加入500ml冰水,用4×100ml甲苯提取。提取液合并,用碳酸氢钾溶液洗至无酸,无水硫酸钠干燥。过滤,浓缩,得92g粗品。经蒸馏,可得76g化合物(IV),收率80%,沸点165℃(≤100Pa)。 77.5g(0.44mo1)对氯苯甲酰氯溶于275ml专用石油(沸点180~220℃)中加热至沸,在20min中,滴加41g(0.1lmo1)化合物(Ⅳ)。加毕,在190-195℃加热2～3h,至无氯化氢放出。冷至40℃,加入200ml乙醚。在室温下结晶后,再放入冰箱过夜。过滤收集结晶,用异丙醚洗,再用乙酸乙酯和异丙醚重结晶,得43.3g化合物(I),收率78%。化合物(I)再如方法2还原为阿西美辛。

合成制备方法

方法1：以在吲哚美辛的合成中得到的N-(4-甲氧基苯基)-4-氯苯甲酰肼为原料，和(3-乙酰基丙酰氧基)乙酸苄酯(其制备见方法3)环合，得到[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-乙酰氧基]乙酸苄酯(I)。得到的苄酯(I)溶于冰醋酸中，在室温下在钯-炭催化剂上进行加氢，当氢吸收停止后，过滤去催化剂，滤液减压浓缩，残液加入石油醚中重结晶，得阿西美辛精品，熔点149.5～150.5℃，收率93%。
                                                     方法2：以吲哚美新为原料。
        在搅拌下，将180g(0.503mo1)吲哚美新溶于900ml无水二甲基甲酰胺，加入35g(0.253mo1)磨细和干燥的碳酸钾，在50℃下搅拌45min。在15min中，滴入128g(0.56mo1)溴乙酸苄酯，在50℃下搅拌3h。过滤，滤液浓缩，剩余物溶于氯仿，用水洗至中性，无水硫酸钠干燥。浓缩，异丙醚-乙酸乙酯重结晶，得228g化合物(I)，收率89.5%，熔点96℃。
60g(0.12mo1)化合物(I)溶于700ml乙酸乙酯，加入6g 5%钯-炭催化剂，在40℃下氢化1h，吸收约2.921L氢气(20℃)。过滤，浓缩，往剩余物加入石油醚(40～60℃)，使结晶完全，并在冰箱中放置12h。过滤，先空气中干燥，后真空干燥，得46g阿西美辛，收率93%，熔点150～153℃。
方法3：以对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯为原料。(3-乙酰基丙酰氧基)乙酸苄酯的制备。93.5g(0.68mo1)干燥碳酸钾悬浮于650ml无水二甲基甲酰胺，加热至40℃，在70min内滴入116.1g(1.0mo1)3-乙酰基丙酸。加毕，冷至30℃，加入229.1g(1.0mo1)2-溴乙酸苄酯。在50℃下反应4h。过滤除去无机盐，用甲苯提取。提取液浓缩，剩余物溶于400ml二氯甲烷，水洗至中性，无水硫酸钠干燥。浓缩，剩余物溶于。1000ml异丙醚，加入冷至-25℃的1500ml石油醚(40～60℃)，于-15℃下放置1h。过滤，在22℃下真空干燥，得235g(3-乙酰基丙酰氧基)乙酸苄酯，收率89%，熔点31.5～32.5℃，沸点176～178℃/1.20kPa。
        26.3g(0.19mo1)对甲氧基苯肼溶于125ml冰乙酸和450ml水，在搅拌下，滴入50g(0.19mo1)(3-乙酰基丙酰氧基)乙酸苄酯，再搅拌1h。用甲苯提取，提取液水洗至中性，干燥，浓缩，得75.5g棕色油状的化合物(Ⅱ)，直接用于下列反应。
        将化合物(Ⅱ)直接溶于125ml无水吡啶，加入500ml无水乙醚，再在0℃加入43.5g对氯苯甲酰氯在250ml无水乙醚的溶液，在氮气保护下回流2h，冷却，水洗至中性，干燥，浓缩，得95g化合物(Ⅲ)的粗品。无需提纯，直接用于下步反应。
        将化合物(Ⅲ)直接溶于380ml乙酸，在80℃下加热5min。减压浓缩，剩余物溶于氯仿，用碳酸氢钠溶液洗，并水洗至中性。用氧化铝层析，氯仿洗脱。浓缩后用乙醚重结晶，得10.6g化合物(I)。从对甲氧基苯肼计，收率11%。化合物(I)再如方法2还原为阿西美辛。

                                                                   方法4：对甲氧基苯肼和(3-乙酰基丙酰氧基)乙酸苄酯也可先环合，再对氯苯甲酰化。
        45.7g(0.26mo1)对甲氧基苯肼盐酸盐和69.2g(0.26mo1)(3-乙酰基丙酰氧基)乙酸苄酯溶于260ml乙酸，先在28℃搅拌42h，再在50℃搅拌5h。蒸出150～180ml溶剂后，加入500ml冰水，用4×100ml甲苯提取。提取液合并，用碳酸氢钾溶液洗至无酸，无水硫酸钠干燥。过滤，浓缩，得92g粗品。经蒸馏，可得76g化合物(IV)，收率80%，沸点165℃(≤100Pa)。
         77.5g(0.44mo1)对氯苯甲酰氯溶于275ml专用石油(沸点180~220℃)中加热至沸，在20min中，滴加41g(0.1lmo1)化合物(Ⅳ)。加毕，在190-195℃加热2～3h，至无氯化氢放出。冷至40℃，加入200ml乙醚。在室温下结晶后，再放入冰箱过夜。过滤收集结晶，用异丙醚洗，再用乙酸乙酯和异丙醚重结晶，得43.3g化合物(I)，收率78%。化合物(I)再如方法2还原为阿西美辛。

用途简介

非甾体消炎镇痛药,有明显抑制炎症的作用。适用于风湿性关节炎、类风湿性关节炎、肌纤维组织炎、坐骨神经痛等的治疗。

用途

非甾体消炎镇痛药，有明显抑制炎症的作用。适用于风湿性关节炎、类风湿性关节炎、肌纤维组织炎、坐骨神经痛等的治疗。

物化性质展开↓

外观与性状：
从石油醚得淡黄色细微结晶，熔点150-153℃。急性毒性LD50雄、雌小鼠，雄、雌大鼠(mg/kg)：55.5，18.42，24.2，30.1口服；34.1，51.1，38.1，28.3静脉注射。

密度：
1.36g/cm3

熔点：
151.5°C

沸点：
565.5ºC at 760mmHg

闪点：
295.8°C

折射率：
1.611

其它信息：

1.性状：从石油醚得淡黄色细微结晶。
2.熔点：150-153℃。

安全信息展开↓

包装等级：
II

风险类别：
6.1(a)

海关代码：
2942000000

危险类别码：
R26/27/28

安全说明：
S22-S25-S36/37/39-S45

危险标志：
T+:Verytoxic;

合成路线查看所有的合成路线

53164-04-8

53164-04-8

→

~95%

53164-05-9

阿西美辛

75302-98-6

1-丙酮,1,1'-[6,7,9,10,17,18,20,21-八氢二苯并[b,k][1,4,7,10,13,16]六噁环十八英-2,13(或2,14)-二基]二[2-甲基- (9CI)

→

~77%

53164-05-9

阿西美辛

53164-03-7

Laevulinoyloxyessigsaeurebenzylester

→

53164-05-9

阿西美辛

毒理性展开↓

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NL3521400

CHEMICAL NAME :
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester

CAS REGISTRY NUMBER :
53164-05-9

BEILSTEIN REFERENCE NO. :
0501672

LAST UPDATED :
199612

DATA ITEMS CITED :
24

MOLECULAR FORMULA :
C21-H18-Cl-N-O6

MOLECULAR WEIGHT :
415.85

WISWESSER LINE NOTATION :
T56 BNJ BVR& C1 D1VO1VQ GO1
HEALTH HAZARD DATA
ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
24200 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
23 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
28400 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
28300 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intramuscular

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
19300 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
18420 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
23300 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
22800 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
34100 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intramuscular

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
27600 ug/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
64200 ug/kg

TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,657,1981

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
200 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intramuscular

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
>100 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - cat

DOSE/DURATION :
>600 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rabbit

DOSE/DURATION :
300 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - guinea pig

DOSE/DURATION :
194 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - guinea pig

DOSE/DURATION :
192 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
280 mg/kg/35D-C

TOXIC EFFECTS :
Gastrointestinal - ulceration or bleeding from stomach Endocrine - other changes Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)

REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,665,1981 ** REPRODUCTIVE DATA **

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
13500 ug/kg

SEX/DURATION :
female 17-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,777,1981

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
56 mg/kg

SEX/DURATION :
female 16-22 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
44 mg/kg

SEX/DURATION :
female 7-17 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Newborn - behavioral

REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,765,1981

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
88 mg/kg

SEX/DURATION :
female 7-17 day(s) after conception

TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - live birth index (measured after birth)

REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,765,1981

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
108 mg/kg

SEX/DURATION :
female 17-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,777,1981

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
351 mg/kg

SEX/DURATION :
female 6-18 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1398,1980

毒理学数据：

急性毒性LD₅₀雄、雌小鼠，雄、雌大鼠(mg/kg)：55.5，18.42，24.2，30.1口服；34.1，51.1，38.1，28.3静脉注射。

MSDS 展开↓

SECTION 1: Identification of the substance/mixture and of the company/undertaking
  Product identifiers
    Product name        : Acemetacin
    REACH No.        : A registration number is not available for this substance as the substance
    or its uses are exempted from registration, the annual tonnage does not
    require a registration or the registration is envisaged for a later
    registration deadline.
    CAS-No.        : 53164-05-9
  Relevant identified uses of the substance or mixture and uses advised against
    Identified uses        : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
  Classification of the substance or mixture
  Classification according to Regulation (EC) No 1272/2008
    Acute toxicity, Inhalation (Category 1), H330
    Acute toxicity, Dermal (Category 2), H310
    Acute toxicity, Oral (Category 2), H300
    For the full text of the H-Statements mentioned in this Section, see Section 16.
  Classification according to EU Directives 67/548/EEC or 1999/45/EC
    T+ Very toxic        R26/27/28
    For the full text of the R-phrases mentioned in this Section, see Section 16.
  Label elements
  Labelling according Regulation (EC) No 1272/2008
    Pictogram
    Signal word        Danger
    Hazard statement(s)
    H300        Fatal if swallowed.
    H310        Fatal in contact with skin.
    H330        Fatal if inhaled.
    Precautionary statement(s)
    P260        Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
    P264        Wash hands thoroughly after handling.
    P280        Wear protective gloves/ protective clothing.
    P284        Wear respiratory protection.
    P302 + P350        IF ON SKIN: Gently wash with plenty of soap and water.
    P310        Immediately call a POISON CENTER or doctor/ physician.
    Supplemental Hazard        none
    Statements
  Other hazards - none

SECTION 3: Composition/information on ingredients
  Substances
    Chemical characterization : Natural product
    Synonyms        : 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
    carboxymethyl ester
    Formula        : C21H18ClNO6
    Molecular Weight        : 415,82 g/mol
    CAS-No.        : 53164-05-9
    EC-No.        : 258-403-4
  Hazardous ingredients according to Regulation (EC) No 1272/2008
    Component        Classification        Concentration
  Acemetacin
    CAS-No.        53164-05-9        Acute Tox. 1; Acute Tox. 2;        <= 100 %
    EC-No.        258-403-4        H300, H310, H330
  Hazardous ingredients according to Directive 1999/45/EC
    Component        Classification        Concentration
  Acemetacin
    CAS-No.        53164-05-9        T+, R26/27/28        <= 100 %
    EC-No.        258-403-4
    For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
  Description of first aid measures
  General advice
    Consult a physician. Show this safety data sheet to the doctor in attendance.
  If inhaled
    If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
  In case of skin contact
    Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
  In case of eye contact
    Flush eyes with water as a precaution.
  If swallowed
    Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
  Most important symptoms and effects, both acute and delayed
    The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
    section 11
  Indication of any immediate medical attention and special treatment needed
    no data available

SECTION 5: Firefighting measures
  Extinguishing media
  Suitable extinguishing media
    Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
  Special hazards arising from the substance or mixture
    Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
  Advice for firefighters
    Wear self contained breathing apparatus for fire fighting if necessary.
  Further information
    no data available

SECTION 6: Accidental release measures
  Personal precautions, protective equipment and emergency procedures
    Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
    adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
    For personal protection see section 8.
  Environmental precautions
    Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
  Methods and materials for containment and cleaning up
    Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
    containers for disposal.
  Reference to other sections
    For disposal see section 13.

SECTION 7: Handling and storage
  Precautions for safe handling
    Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
    Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
    protection.
    For precautions see section 2.2.
  Conditions for safe storage, including any incompatibilities
    Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
  Specific end use(s)
    Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
  Control parameters
  Components with workplace control parameters
  Exposure controls
  Appropriate engineering controls
    Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
    the product.
  Personal protective equipment
  Eye/face protection
    Face shield and safety glasses Use equipment for eye protection tested and approved under
    appropriate government standards such as NIOSH (US) or EN 166(EU).
  Skin protection
    Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
    (without touching glove's outer surface) to avoid skin contact with this product. Dispose of
    contaminated gloves after use in accordance with applicable laws and good laboratory practices.
    Wash and dry hands.
    The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
    the standard EN 374 derived from it.
    Full contact
    Material: Nitrile rubber
    Minimum layer thickness: 0,11 mm
    Break through time: 480 min
    Material tested:Dermatril® (KCL 740 / Z677272, Size M)
    Splash contact
    Material: Nitrile rubber
    Minimum layer thickness: 0,11 mm
    Break through time: 480 min
    Material tested:Dermatril® (KCL 740 / Z677272, Size M)
    data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300,     test method: EN374
    If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
    contact the supplier of the CE approved gloves. This recommendation is advisory only and must
    be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
    anticipated use by our customers. It should not be construed as offering an approval for any
    specific use scenario.
  Body Protection
    Complete suit protecting against chemicals, The type of protective equipment must be selected
    according to the concentration and amount of the dangerous substance at the specific workplace.
  Respiratory protection
    Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
    respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
    controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
    respirators and components tested and approved under appropriate government standards such
    as NIOSH (US) or CEN (EU).
  Control of environmental exposure
    Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

SECTION 9: Physical and chemical properties
  Information on basic physical and chemical properties
    a) Appearance        Form: solid
    b) Odour        no data available
    c) Odour Threshold        no data available
    d) pH        no data available
    e) Melting point/freezing        no data available
    point
    f) Initial boiling point and no data available
    boiling range
    g) Flash point        no data available
    h) Evapouration rate        no data available
    i) Flammability (solid, gas) no data available
    j) Upper/lower        no data available
    flammability or
    explosive limits
    k) Vapour pressure        no data available
    l) Vapour density        no data available
    m) Relative density        no data available
    n) Water solubility        no data available
    o) Partition coefficient: n- no data available
    octanol/water
    p) Auto-ignition        no data available
    temperature
    q) Decomposition        no data available
    temperature
    r) Viscosity        no data available
    s) Explosive properties        no data available
    t) Oxidizing properties        no data available
  Other safety information
    no data available

SECTION 10: Stability and reactivity
  Reactivity
    no data available
  Chemical stability
    Stable under recommended storage conditions.
  Possibility of hazardous reactions
    no data available
  Conditions to avoid
    no data available
  Incompatible materials
    no data available
  Hazardous decomposition products
    Other decomposition products - no data available
    In the event of fire: see section 5

SECTION 11: Toxicological information
  Information on toxicological effects
  Acute toxicity
    LD50 Oral - rat - 24,2 mg/kg
  Skin corrosion/irritation
    no data available
  Serious eye damage/eye irritation
    no data available
  Respiratory or skin sensitisation
    no data available
  Germ cell mutagenicity
    no data available
  Carcinogenicity
    IARC:        No component of this product present at levels greater than or equal to 0.1% is identified as
    probable, possible or confirmed human carcinogen by IARC.
  Reproductive toxicity
    no data available
  Specific target organ toxicity - single exposure
    no data available
  Specific target organ toxicity - repeated exposure
    no data available
  Aspiration hazard
    no data available
  Additional Information
    RTECS: NL3521400
    To the best of our knowledge, the chemical, physical, and toxicological properties have not been
    thoroughly investigated.

SECTION 12: Ecological information
  Toxicity
    no data available
  Persistence and degradability
    no data available
  Bioaccumulative potential
    no data available
  Mobility in soil
    no data available
  Results of PBT and vPvB assessment
    PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
  Other adverse effects
    no data available

SECTION 13: Disposal considerations
  Waste treatment methods
  Product
    Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
    professional waste disposal service to dispose of this material. Dissolve or mix the material with a
    combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
  Contaminated packaging
    Dispose of as unused product.

SECTION 14: Transport information
  UN number
    ADR/RID: 2811        IMDG: 2811        IATA: 2811
  UN proper shipping name
    ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (Acemetacin)
    IMDG: TOXIC SOLID, ORGANIC, N.O.S. (Acemetacin)
    IATA:        Toxic solid, organic, n.o.s. (Acemetacin)
  Transport hazard class(es)
    ADR/RID: 6.1        IMDG: 6.1        IATA: 6.1
  Packaging group
    ADR/RID: II        IMDG: II        IATA: II
  Environmental hazards
    ADR/RID: no        IMDG Marine pollutant: no        IATA: no
  Special precautions for user
    no data available

SECTION 15: Regulatory information
    This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
  Safety, health and environmental regulations/legislation specific for the substance or mixture
    no data available
  Chemical Safety Assessment
    For this product a chemical safety assessment was not carried out

SECTION 16: Other information
  Full text of H-Statements referred to under sections 2 and 3.
    Acute Tox.        Acute toxicity
    H300        Fatal if swallowed.
    H310        Fatal in contact with skin.
    H330        Fatal if inhaled.
  Full text of R-phrases referred to under sections 2 and 3
    T+        Very toxic
    R26/27/28        Very toxic by inhalation, in contact with skin and if swallowed.
  Further information
    Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
    only.
    The above information is believed to be correct but does not purport to be all inclusive and shall be
    used only as a guide. The information in this document is based on the present state of our knowledge
    and is applicable to the product with regard to appropriate safety precautions. It does not represent any
    guarantee of the properties of the product. Corporation and its Affiliates shall not be held
    liable for any damage resulting from handling or from contact with the above product. See
     and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

分子结构与计算化学数据展开↓

分子结构数据

1、摩尔折射率：106.05
2、摩尔体积（cm³/mol）：305.4
3、等张比容（90.2K）：809.7
4、表面张力（dyne/cm）：49.4
5、极化率（10-24cm3）：42.04

计算化学数据

1.疏水参数计算参考值（XlogP）:无
2.氢键供体数量:1
3.氢键受体数量:6
4.可旋转化学键数量:7
5.互变异构体数量:无
6.拓扑分子极性表面积94.8
7.重原子数量:29
8.表面电荷:0
9.复杂度:620
10.同位素原子数量:0
11.确定原子立构中心数量:0
12.不确定原子立构中心数量:0
13.确定化学键立构中心数量:0
14.不确定化学键立构中心数量:0
15.共价键单元数量:1

上下游相关产品

上游产品
更多

75302-98-6

1-丙酮,1,1'-[6,7,9,10,17,18,20,21-八氢二苯并[b,k][1,4,7,10,13,16]六噁环十八英-2,13(或2,14)-二基]二[2-甲基- (9CI)

53164-04-8

N/A

19501-58-7

4-甲氧基苯肼盐酸盐

53-86-1

吲哚美辛

123-76-2

乙酰丙酸

阿西美辛

基本信息 展开↓

生产制备方法及用途展开↓

制备方法

合成制备方法

用途简介

用途

物化性质展开↓

安全信息展开↓

合成路线查看所有的合成路线

毒理性展开↓

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MSDS 展开↓

分子结构与计算化学数据展开↓

分子结构数据

计算化学数据

上下游相关产品

上游产品

基本信息展开↓